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ABSTRACT 
Predictors of response of AIDS-associated Kaposi-Sarcoma to standard 
chemotherapy 
Overview: 
Kaposi Sarcoma is the most common HIV-associated cancer. Its etiology and 
pathogenesis is not fully understood. Little is known about what predicts prognosis, 
survival and therapeutic response in HIV-KS. In South Africa given the high 
seroprevalence rates of HIV-l and human herpes virus 8 (HHV 8), Kaposi's sarcoma 
is a significant problem. The majority of patients have been treated solely with 
palliation due to the poor outcome associated with a diagnosis of HIV-KS, more so in 
the absence of highly active antiretroviral therapy (HAART). Since the national ARV 
rollout programme and the availability and accessibility of HAART to all patients with 
a diagnosis of HIV-KS, a new strategy has to be established to enable adequate 
patient selection for chemotherapy. There have been a few published studies 
addressing the predictors of response to chemotherapy in the first world. However, 




To identify and assess the potential value of several parameters predictive of 
outcome, survival and therapeutic response in HIV- infected patients with KS. Clinical, 
hematological, biochemical, immunological and virological variables were evaluated. 
Methods: 
We collected data from 25 patients with AIDS-KS who were enrolled in a phase III 
randomized controlled trial comparing HAART alone with the combination of HAART 
and chemotherapy. All patients were from the combination therapy arm. The 
following variables were evaluated as predictors of prognosis and therapeutic 
response: age, gender, ethnic origin, Haemoglobin (Hb), white blood cells (WBCs), 
lymphocytes, neutrophils, platelets, S.albumin, ALP, GGT, CD4 count, HIV viral load. 
These variables were assessed in patients at baseline and month 6 of therapy. 
Patients were staged into good risk and poor risk according to the AIDS clinical trial 
group (ACTG) criteria. The outcomes assessed were response to treatment and 
mortality. 
Results: 
A total of 25 patients participated to the study. Of these 16(64%) were males and 
9(36%) were females, with male: female ratio of 2.7:1. Median age was 34 years 
(24-47); all patients were of Black African origin. Of the 21 patients, 15 (71.4%) were 
of good prognosis and 6(28.6%) were of poor prognosis. 
xu 
At baseline the median values of the different variables were as follows: Hb 10.9 g/dl, 
WBCs 5.95x109/L, lymphocytes 1.7 x109/L, neutrophils 3 x10
9
/L, platelets 272 x10
9
/L, 
S.albumin 30 gil, total protein 88 gil, ALP 64 U/L, and GTT 21 U/L, CD4 count was 
255 cells/mm 3 , HIV-RNA viral load was 42000( 4.610gs). 
At month 6, 22 patients remained alive, their median values were: Hb 12.2 g/dl, 
WBCs 4.65 x109/L, lymphocytes 1.5 x109/L, neutrophils 3 x10
9
/L, platelets 301 
x109/L, S.albumin 36.5 gil, total protein 84.5 gil, ALP 78.5 U/L, GTT 44.5 U/L, CD4 
count 288 cells/mm 3 , HIV-RNA viral load was 50500( 4.6910gs). 
The baseline median CD4 and HIV-RNA viral load counts for the 3 patients who died 
before month 6 were 47 cells/mm3 and 31000(4.610gs); respectively. 
Response to therapy was evaluated in 21(84%) patients as 4(16%) patients were 
missing, of the 21 patients 3 (14.3%) had complete response and 18(85.7%) had 
partial response. With respect to sex 2(14.3%) males had complete response and 
12(85.7%) had partial response, 1(14.3%) female had complete response and 6 
(85.7%) had partial response. 
Non-parametric statistics were used because of the small sample size and the 
skewness of the data. Variables were described using medians and ranges, and 
compared between two independent groups using Mann-Whitney tests. Baseline and 
Xlll 
month 6 comparisons were done using Wilcoxon signed ranks tests. Receiver 
Operating Characteristic (ROC) curves were used to analyze cut points to optimize 
sensitivity and specificity of a quantitative variable for a dichotomous outcome. 
Discussion 
In the univariate analysis age and sex didn't influence prognosis and therapeutic 
response, the influence of ethnic origin couldn't be assessed as all patients were of 
the same ethnic origin. Baseline WBCs (P= 0.004) and lymphocytes (P=0.026) were 
significantly associated with complete response. Higher values of GGT (p=O.OOl); 
ALP (P=0.006) were associated with more deaths. 
Baseline CD4 count and HIV viral load were not of predictive value, although change 
CD4 (P=002) and VL (p=.OOO) over time was significant and most likely attributed to 
response to therapy. 90.9 % of patients reached undetectable HIV-l Viral loads at 
month 6. 
CONCLUSION: 
Neither CD4 count nor HIV viral load at baseline predicted prognosis or survival; 
however there was a borderline significance of CD4 (P=0.058) towards a better 
survival. 
XIV 
Both CD4 count and HIV viral load were significantly changed over time that might be 
attributed to therapeutic effect. 
Simple hematological (WBCs & lymphocytes) and biochemical (GGT& ALP) tests can 
be useful in predicting therapeutic response and survival in patients with AIDS-KS 
especially where resources are limited. 
Further studies with a larger sample size and longer period of evaluation are 
recommended to evaluate these parameters in order to establish clearer guidelines 





1. HIV Epidemic 
Cancer and AIDS are both pandemics: they both cause psychological, emotional 
and social disruption that influence life as much as their physical impact [1]. The 
HIV epidemic was first identified in 1981 in homosexual males in Los Angeles and 
New York where atypical Pneumocystis carinii pneumonia cases were noted. This 
was found to be related to an immune deficiency, which had additional clinical 
consequences, including other forms of opportunistic infection; Kaposi's sarcoma 
and other malignancies. Kaposi's sarcoma is an AIDS defining malignancy in the 
presence of a positive HIV test [1]. 
1.1 HIV and AIDS Epidemic in the world 
There are 42 million people living with HIV / AIDS worldwide. 38.6 million of these 
are adults; 19.2 million are women and 3.2 million are children under the age of 
15. In 2002 five million people became infected with HIV, of which 4.2 million 
were adults and 2 million of them were women. HIV-related causes resulted in 3.1 
million deaths in the year 2002, another new 5 million people became infected 
with HIV in 2003, this was the highest number since HIV was identified as an 
epidemic. At the global level, the number of people living with HIV continue to 
grow. Over 20 million have died as a consequence of HIV infection since AIDS was 
identified in 1981.The total number of people living with the human 
immunodeficiency virus (HIV) rose in 2004 to reach its highest level: an estimated 




infection in 2004 [2]. The estimated number of people living with HIV is shown in 
Figure 1. 
Figure 1: estimated number of people living with HIV 2002-2004 [3]. 
Sub-Saharan Africa has the highest prevalence of HIV (two thirds of people living 
with HIV / AIDS). South and South-East Asia has the second highest prevalence of 
HIV world wide (6 - 7 millions). There are 980,000 people living with HIV/AIDS in 
North America, 570,000 in Western Europe and 1.2 million in Eastern Europe and 
Central Asia. In Australia and New Zealand the number of HIV-infected people has 
remained constant since 2001 (15,000 people). Latin America and the Caribbean 
have 1.5 million and 440,000 HIV-infected individuals; respectively. East Asia and 
the Pacific have 1.2 million people living with HIV / AIDS. North Africa and the 
Middle East have 550,000 people living with HIV/AIDS [3]. The extent and impact 
of epidemic varies with different regions; some countries are more affected than 
others and within different areas of the same country, there are usually wide 




1.2. HIV in Africa 
An estimated 25 million people are living with HIV in Sub-Saharan Africa. Although 
there is an increase in AIDS-related deaths, prevalence rates remain steady due to 
continued increase in new infections. However, prevalence is still rising in some 
countries such as Madagascar and Swaziland, and is declining in others such as 
Uganda. Sub-Saharan Africa is a place of nearly two-thirds of all HIV-infected 
people. In 2003, an estimated three million people became newly infected and 2.2 
million died. There is great diversity across the continent in the levels and trends 
of HIV infection. In southern Africa all seven countries have antenatal prevalence 
rates above 17% with Botswana and Swaziland having prevalence above 35%. In 
West Africa, HIV prevalence is much lower with no country having a prevalence 
above 10% and most having prevalence between one and five percent. Adult 
prevalence in countries in Central and East Africa falls somewhere between these 
two groups, ranging from 4% to 13%. African women are at greater risk, 
becoming infected at an earlier age than men. Today there are on average 13 
infected women for every 10 infected men in sub-Saharan Africa - up from 12 for 
10 in 2002. A review compared the ratio of young women living with HIV to young 
men living with HIV; showed a range of 20 women for every 10 men in South 
Africa to 45 women for every 10 men in Kenya and Mali [3]. In North Africa and 
the Middle East, around 480 000 are living with HIV but systematic surveillance of 
the epidemic is not well developed, particularly among high-risk groups such as 
drug users and homosexual men [3]. 
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1.3. WOMEN AND AIDS 
The HIV epidemic is affecting women in increasing numbers; a global overview of 
the HIV-epidemic showed that approximately half of all people living with HIV are 
females. Women are becoming affected in an increasing proportion in regions 
where heterosexual sex is a dominant mode of HIV transmission, as is the case in 
sub-Saharan Africa and the Caribbean. In sub-Saharan Africa 57% of HIV-infected 
adults are women. In South Africa, Zambia and Zimbabwe, for example, young 
women (aged 15-24 years) are three to six times more likely to be infected than 












Table 1: Regional Statistics for HIV & AIDS end of 2003 [3] 
* Millions 
AIDS-KS 
I ntrod uctio n 
Deaths of adults 
and children* 
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Table 2: Regional HIV and AIDS statistics 2002 & 2004 [3]. 
AIDS-KS 
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2. Malignancy in Acquired Immunodeficiency Syndrome 
Immunodeficiency of multiple aetiologies is associated with an increased risk of 
malignancy. The risk is variable, dependent on the severity and extent of the 
immunologic abnormality, and is not restricted to those individuals considered to 
have a lack of immune reactivity. The combined presence of immune activation 
coupled with immunodeficiency may be the most conducive situation, for the 
appearance of immunodeficiency-related tumours [4]. 
Malignancies have been detected in approximately 40% of all patients with 
acquired immunodeficiency syndrome (AIDS) sometime during the course of their 
illness. These cancers have been both a primary cause of death in some patients 
and also a source of considerable morbidity [5]. The varieties of HIV-associated 
tumours are listed in Table 4 [6]. In general, the epithelial tumours commonly 
seen outside the context of HIV infection are not increased in incidence within the 
context of the AIDS epidemic. However, a relatively narrow range of malignancies 
occurs with increased frequency, in an association with secondary infectious 
processes. In particular, Kaposi's sarcoma (KS) has recently been linked to a 
member of the gamma herpes virus family, KS-associated herpes virus (KSHV) [6, 
7]. This virus, also known as human herpes virus-8 (HHV-8), is also seen in a 
small subset of non-Hodgkin's lymphomas. A far larger proportion of the AIDS-
related lymphomas (ARL) are associated with Epstein-Barr virus (EBV). The 
squamous cell neoplasia seen in AIDS is almost exclusively due to human 




Several tumours are suspected to be of increased incidence, and accumulating 
evidence supports this view; these tumours include Hodgkin1s disease (which is 
EBV-related in most cases of AIDS). Leiomyosarcomas are seen with increased 
frequency in children with HIV infection and are uniformly noted to have EBV 
present within them [10]. Interestingly, this tumour is not noted with increased 
frequency in adults with AIDS, and sporadic leiomyosarcomas are not EBV-related. 
Plasmacytoma appears to occur with increased frequency and has a number of 
interesting features in AIDS; it is the malignant transformation of a cell population 
that is commonly disturbed in HIV infection. Plasma cell overproduction of 
immunoglobulin is the most common serologic abnormality associated with HIV 
infection. Malignant plasmacytoma is occasionally seen and may be associated 
with anti-HIV-specific immunoglobulin-secreting tumours. Of note, there are also 
recent data that suggest that Kaposi Sarcoma herpes virus (KSHV) might 
partiCipate in plasma cell dyscrasias [11], but it is unclear how this virus is 
involved in the plasmacytomas seen in AIDS. The incidence of AIDS-related 
malignancies appears to be altered in the era of protease inhibitor therapy for 
HIV-l. This is particularly notable in KS, where the number of patients requiring 
systemic therapy for this disease has markedly diminished. Similar observations 
have been made regarding the incidence of primary eNS lymphoma, which is 
generally a manifestation of end-stage AIDS. However, the frequency of systemic 
lymphoma in AIDS appears to be far more finely modulated. Definitive 
epidemiologic data regarding these changes are still in evolution. 
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1. Kaposi's sarcoma 
2. Non-Hodgkin's lymphoma 
3. Squamous cell neoplasia 
4. Plasmacytoma 
5. Hodgkin's disease 
6. Leiomyoma/leiomyosarcoma 




3. KAPOSI'S SARCOMA 
3.1 General introduction: 
Kaposi's sarcoma (KS) was described initially in 1872 by Hungarian dermatologist, 
Moritz Kaposi in 5 patients presenting with "sarcoma idiopathic multiple 
hemorrhagicum" [12]. From that time until the current human immunodeficiency 
virus (HIV) disease epidemic identified with the Acquired Immunodeficiency 
Syndrome (AIDS), KS remained a rare tumour. In 1912 Sternberg termed this 
disease Kaposi's sarcoma - now referred to as classical Kaposi's sarcoma, while 
most of the cases seen in Europe and North America have occurred in elderly men 
of Italian or Eastern European Jewish ancestry, the neoplasm also occurs in 
several other distinct populations: young black African adult males, young 
children, renal allograft reCipients, and other patients receiving immuno-
suppressive therapy. The disseminated, fulminant form of KS associated with HIV 
disease is referred to as epidemic KS to distinguish it from the classic, African and 
transplant-related varieties of the neoplasm. In addition, KS has been identified in 
homosexual men apart from the HIV disease epidemic [13]. 
Although the histopathology of the different types of the Kaposi's tumour is 
essentially identical in all of these groups, the clinical manifestations and course of 
the disease differs dramatically [14]. A key piece to the dilemma of KS 
pathogenesis was the 1994 discovery of a gamma herpes virus, human herpes 
virus type 8 (HHV-8), also known as Kaposi's sarcoma herpes virus [15]. HHV-8 




transplant-related, and AIDS-associated KS, but was absent from non-involved 
tissue [16-19]. 
Kaposi Sarcoma is a spindle-cell tumour thought to be derived from endothelial 
cell lineage; this condition carries a variable clinical course ranging from minimal 
mucocutaneous disease to extensive organ involvement. Kaposi Sarcoma can 
occur in several different clinical settings. 
3.2 Types of Kaposi's sarcoma 
3.2.1 Classic Kaposi's sarcoma 
Classic KS is a rare disease, occurs more often in males, with a ratio of 
approximately 10 to 15 males to 1 female [20]. In North Americans and 
Europeans, the usual age at onset is between 50 and 70 years of age [20]. 
Patients usually present with single or multiple asymptomatic red, purple, or 
brown patch, plaque, or nodular skin lesion. The disease is often limited to lower 
extremities, especially involving the ankle and soles [20]. Classic Kaposi's sarcoma 
usually runs a relatively benign, indolent course for 10 to 15 years or more with 
slow enlargement of the original tumours and the gradual development of 
additional lesions. Lymphedema and venous stasis of the involved lower extremity 
are frequent complications. Systemic lesions can develop in long standing cases, 
along the gastrointestinal tract, lymph nodes, and other organs [20]. 
These visceral lesions are generally asymptomatic and are most often discovered 




third of the patients with classic KS develop a second primary malignancy, most 
often non-Hodgkin's lymphoma [21-23]. 
3.2.2. African Kaposi's sarcoma 
Kaposi sarcoma was recognized as a relatively common neoplasm endemic in 
native populations in equatorial Africa in 1950, it comprised approximately 9% of 
all cancers seen in Ugandan males. African KS is observed as an indolent 
neoplasm identical to the classic disease seen in Europe and North America or as 
an aggressive disease with fungating and exophytic tumours that may invade the 
subcutaneous and surrounding tissue including the underlying bone. In Africa, 
both the indolent and locally more aggressive forms of KS occur with a male to 
female ratio comparable to that observed with the classic KS tumour seen in North 
America and Europe. However, patients in Africa are seen at younger ages than 
their European counterparts. Lymphadenopathic form of KS is also seen in Africa 
primarily in children (male: female ratio 3:1). In these cases, the generalized 
lymphadenopathy is frequently associated with visceral organ involvement. The 
prognosis is very poor, with a 100% fatality rate within 3 years [24, 25]. 
3.2.3 Immunosuppressive treatment-related Kaposi sarcoma 
Kaposi sarcoma in association with immunosuppression in a renal transplant 
patient was first described in 1969. Since then, a number of renal and other organ 
allograft recipients receiving immunosuppressive therapy (Prednisone and 
Azathioprine) have developed KS shortly after the onset of immunosuppressive 




KS of 150 to 200 times higher than in the general population. The average time to 
develop KS after transplantation is about 16 months. Although the tumour in these 
iatrogenically immunosuppressed patients often remain localized to the skin, 
widespread dissemination with mucocutaneous or visceral organ involvement is 
common. Tn some cases, the KS tumours have regressed as a result of reduction 
or changes in immunosuppressive therapy. Clinical management of renal 
transplant patients who develop KS is difficult and requires a balance between the 
risk of death from generalized KS and the risk of graft rejection and complications 
of renal failure that may occur if the immunosuppressive therapy is discontinued 
[20,26]. 
3.2.4 Epidemic Kaposi sarcoma 
A fulminant and disseminated form of KS in young homosexual or bisexual men 
was first reported IN 1981 as part of an epidemic now known as AIDS [27]. The 
underlying immunologic deficiency that characterizes HIV disease is an acquired 
disorder of cell-mediated immune functions. This immunologic deficiency and 
immune dysregulation predisposes the host to a variety of opportunistic infections 
and unusual neoplasms, especially KS. HIV itself may play an indirect role in the 
development of KS [28]. Approximately 95% of all the cases of epidemic KS in the 
United States have been diagnosed in homosexual or bisexual men. In the past, 
approximately 26% of all homosexual males with HIV disease presented with, or 
eventually developed KS during the course of their illness. By comparison, less 
than 3% of all heterosexual intravenous drug users with HIV disease developed 




the epidemic was first identified in 1981 [29]. About 48% of AIDS patients in 1981 
had KS as their presenting AIDS diagnosis. By August 1987, the cumulative 
proportion of AIDS patients with KS had diminished to less than 20%. The 
introduction of highly active antiretroviral therapy (HMRT) may delay or prevent 
the emergence of drug-resistant HIV strains, significantly decrease viral load, lead 
to increased survival, and lessen the risk of opportunistic infections [30, 31]. The 
use of HMRT might possibly be related to the continuing decrease (12%) in the 
incidence of KS as an AIDS-defining illness. Epidemic KS is usually characterized 
by multifocal, widespread lesions at the onset of illness [32]. These lesions may 
involve the skin; oral mucosa; lymph nodes; and visceral organs, such as the 
gastrointestinal tract, lung, liver and spleen. Most patients with HIV disease who 
present with the mucocutanoeus lesions of KS feel healthy and are usually free of 
systemic symptoms as compared to those patients with HIV disease that first 
develop an opportunistic infection. Sites of disease at presentation of epidemic KS 
are much more varied than those seen in the other types of this neoplasm. In an 
early report on the clinical manifestations of the disease, 49 patients were 
described; eight percent had no skin involvement, 27% had localized or fewer 
than 5 skin lesions and 63% had innumerable skin lesions widely distributed over 
the skin surface area. Sixty-one percent of the patients had generalized 
lymphadenopathy at the time of the first examination. Four of these patients who 
had generalized lymphadenopathy in the absence of skin lesions or detectable 
visceral organ involvement at the time of presentation were found to have biopsy-
proven KS localized to the lymph nodes. In 45% of the patients studied, KS lesions 
were found in one or more sites along the gastrOintestinal tract. Twenty-nine 
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percent of the patients had either unexplained fever or weight loss when first 
seen. While most patients present with skin disease, KS involvement of lymph 
nodes or the gastrointestinal tract may occasionally precede the appearance of the 
cutaneous lesions. Eventually, almost all patients with epidemic KS develop 
disseminated disease [20, 32]. 
Progression often proceeds in an orderly fashion from a few localized or 
widespread mucocutaneous lesions to more numerous and generalized skin 
disease with lymph node, gastrointestinal tract disease, and other organ 
involvement. Pleuropulmonary KS is an ominous sign usually occurring late in the 
course of the disease, especially in those patients whose death is directly 
attributed to KS. Most patients with epidemic KS die of one or more complicating 
opportunistic infections. 
3.2.5 Non-epidemic Kaposi sarcoma 
There have been several reports documenting KS in homosexual men who 
persistently have no eVidence of HIV infection. These patients have an indolent 
and cutaneous form of the disease, with new lesions appearing every few years. 
Lesions Occur most commonly on the extremities and genitalia but can Occur 
anywhere on the skin [33]. These cases may indicate the presence of causal 
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3.3 Aetiology & Pathogenesis: 
Kaposi's sarcoma (KS) remains the most commonly diagnosed malignancy in HIV 
infected people. The aetiology of KS remains unknown but evidence suggests that 
the disease is promoted by the effects of immunosuppression and immune 
activation, possibly combined with a sexually transmissible infectious agent. The 
exact cause of AIDS-KS is presently unknown and causes appear to be multiple. 
Kaposi Sarcoma is now known to be associated with V -2 herpes virus designated 
HHV-8, also known as Kaposi Sarcoma herpes virus (KSHV). 
The pathogenesis of Kaposi's sarcoma is better understood since the identification 
of the novel human herpes virus 8 (HHV8) which can be found in all forms of KS. 
Viral oncogenesis and cytokine induced growth as well as some states of 
immunocompromise contribute to its development [34]. Various pro-inflammatory 
cytokine growth factors can stimulate the proliferation and growth of KS cells, 
these include tumor necrosis factor a, interferon 6, fibroblast growth factor, and 
vascular endothelial growth factor (VEGF) resulting in a hyperplasic polyclonal 
lesions with predominant spindle cells derived from lymphoid endothelial tissue 
[34]. 
Several virally encoded genes - e.g., bcl-2, interleukin 6, Cyclin D, G- protein 
coupled receptor and interferon regulatory factors (IRF) provide key function on 
cellular proliferation. Cyclin D increases the proportion of the actively cycling cells, 
production of bcl-2 analogue (vbcl-2) and a protein (vFLIP) both of which will 
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prevent apoptosis; G- protein coupled receptor (GPCR) stimulates angiogenesis by 
producing angiogenic protein which is also inhibitory to macrophages [34]. 
3.4 HHV-8 its discovery and disease associations 
From the earliest days of the AIDS pandemic, it has been clear that patients with 
HIV disease are at increased risk for neoplastiC events. AIDS patients are 
excessively at risk for developing KS (20,000 times that of the general population 
and 70 times that of other immunosuppressed populations) [35]. Early concepts of 
AIDS-KS biogenesis linked KS development primarily to HIV infection. The HIV 
genome was not found within KS tumour cells, so any involvement of HIV in KS 
tumorigenesis would have to be indirect. Evidence for such indirect involvement 
was advanced by studies showing that HIV-infected cells can produce extracellular 
factors that potentiate the growth of KS tumour cells in vitro [36, 37,38,3 
9]. 
The search for a new virus in KS tumours was then motivated by epidemiologic 
studies that pOinted to the involvement of a sexually transmitted factor other than 
HIV in KS tumorigenesis [40]. 
A major breakthrough occurred in 1994 when HHV8 or Kaposi Sarcoma Herpes 
virus (KSHV) was first identified by Chang, Moore, and their collaborators [41], on 
the basis of DNA sequences detected in tissues from patients of AIDS-KS. Human 
herpes virus 8 (HHV8) has also been identified in classic KS, endemic African KS, 
and transplant- related KS [42]. The technique based on the polymerase chain 
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reaction (PCR), identified 2 small fragments of DNA that were reproducibly present 
in AIDS-KS specimens but absent in most non-KS tissues .The nucleotide 
sequences of these 2 fragments revealed 2 gamma- (lymphotropic) herpesviruses, 
indicating that these fragments were derived from a novel herpes viral genome. 
These sequences are found in virtually all AIDS-KS tumours [43]; and are not 
found in most normal tissues derived from patients at low risk for KS. Subsequent 
work has shown that the sequences are also found in KS specimens from HIV-
negative individuals [43 -44]. 
The spectrum of HHV-8-related diseases has not been completely described to 
date. In addition to KS, HHV-8 may also cause other tumours such as primary 
effusion lymphoma (PEL) and multicentric Castleman's disease (MCD). Human 
herpes virus 8 (HHV-8) recently has been associated with primary pulmonary 
hypertension in 2 small studies [45-47], while a primary HHV-8 infection 
syndrome" was described in immunocompetent children [48]. Improvements in 
molecular biologic techniques and increased understanding about the 
pathogenesis of HHV-8 infection may result in the description of additional human 
illnesses associated with HHV-8 infection. 
3.5 The Epidemiology of HHV-8 
DNA Sequences of herpesvirus were identified in almost 100% of amplifiable 
samples from AIDS patients with Kaposi's sarcoma (KS) and 15% of non-KS tissue 
samples from AIDS patients. As HHV-8 cannot be cultivated readily, the diagnosis 
of infection with HHV-8 relies either on assessing the antibody response to 
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infection or on detecting viral nucleic acid in clinical specimens. Using various 
serologic assays, many studies have found that the seroprevalence of HHV-S 
infection varies widely, from approximately 1-3% of blood donors and up to 35 % 
of homosexual men in North America to more than 70% in regions of Africa where 
HHV-S is endemic. At least S5% of patients with Kaposi's sarcoma have antibodies 
to HHV-S. The prevalence of HHV-S infection approximately corresponds to the 
prevalence of KS. A relatively high seroprevalence of Human herpes virus S(HHV-
S) has been described among injection drug users and women with multiple 
sexual partners, [49, 50]. HHV-S seroprevalence also has been shown to be higher 
among family members of HHV-S-seropositive persons [51, 52]. The virus may 
also occasionally be transmitted vertically from mother to child. HHV-S has been 
transmitted by renal allografts, and two kidney transplant recipients have 
subsequently developed Kaposi's sarcoma. 
3.6 Virology, genome organization and molecular epidemiology of HHV8 
Significant advances have been made in the basic understanding of the virology 
of HHV-S infection since its discovery. The entire HHV-S genome has been 
sequenced and the structure of the virion has been established. The tissue tropism 
of the virus been elucidated. The genes and gene products associated with latency 
and lytic replication have been characterized. Human herpes virus S (HHVS) is the 
first human v-herpesvirus and has a tropism for lymphocytes, endothelial cells, 
keratinocytes and possibly marrow stromal cells. The HHV-S genome is housed in 
an icosahedral capsid of approximately 1200 angstroms in diameter with a typical 





for a size of 120-150 nm [53, 54]. The genome is a linear, double-stranded DNA 
of about 165-170 kilobases in length [54]. The complete HHV-8 genome has 
sequence similarities to other v-herpes viruses including, herpesvirus saimirilarities 
(HVS), Epstein - Barr virus (HHV-4) and murine V- herpesvirus 68 (MHV68) [55] 
.The genome contains over 80 open reading frames arranged in a long unique 
region flanked by multiple 801bp terminal repeat units of high G+C content. The 
long unique region contains blocks of conserved genes found in most herpes 
viruses, interspersed with blocks of non-homologous genes that are specific for 
HHV-8 and related viruses [53]. HHV-8 proteins with recognizable homology to 
cellular proteins include: complement binding protein (ORF 4), IL6-like cytokine 
(ORF K2), three chemokines (ORF K4, ORF K4.1 and ORF K6), BcI-2 (ORF 16) 
anti-apoptotic factor, interferon regulatory factor (ORF Kg), D-type Cyclin (ORF 
72), FUCE inhibitory protein (ORF K13), cell adhesion-like molecule (ORF K14) G-
protein coupled receptor (ORF 74).HHV-8 has a number of genes such as ORF K12 
(encodes the highly expressed transcript, kaposin), and ORF K1, a transmembrane 
protein that interacts with immunoreceptor kinases, which are likely to playa role 
in tumorigenesis [53]. Functional studies suggest that these pirated genes may 
help the virus to evade immune responses, prevent cell cycle shutdown and 
interrupt activation of apoptotic pathways. This strategy has been referred to as 
"molecular piracy" of host cell genes. HHV-8 encodes a number of 
immunomodulatory factors: 
Fas signalling in (virus-infected) target cells are triggered by Fas receptor 
multimerization on binding with membrane-bound Fas-L. Subsequent recruitment 
of the adaptor molecule Fas-activated death domain (FADD) leads to upstream 
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caspase (caspase 8) autoactivation and release, leading to downstream effector 
capsase activation (caspase-3, -6, -7) & apoptosis. Death-receptor triggered 
apoptosis can be inhibited at several points: at the initiator stage by FLIP or in the 
amplification loop by bcl-2. HHV-8 v-FLIP blocks apoptosis in virus-infected cells. 
In addition, the virus also encodes a decoy (non-signalling) Fas receptor [53]. 
CTL/NKcell 






Figure 2: Molecular organization of HHV8 [adapted from 53] 
Evidence suggests that one of the genes of HHV-8, vGPCR (viral G-protein coupled 
receptor) acts as a vascular switch, turning on synthesis of a powerful angiogenic 
agent, vascular endothelial growth factor (VEGF), which is responsible for the 
development of KS. However, HHV-8 also contains a considerable number of other 
'pirated' cellular genes in an 'oncogenic cluster' within the virus genome which 





3.7 Sites of disease: 
Kaposi Sarcoma most commonly involves the skin; although involvement of the 
lymph nodes, the oral cavity, and gastrointestinal tract are often seen at 
presentation. Visceral lesions most commonly involve the stomach, bowel, liver, 
spleen, and lungs. Lesions are found in the GI tract in 40% of cases at diagnosis, 
up to 80% at autopsy, and are frequently a symptomatic. Pulmonary involvement, 
often occurring late in the disease, may cause severe respiratory symptoms and is 
associated with poor prognosis. 
3.8 Staging classification of Kaposi's sarcoma: 
Several staging systems for KS have been proposed. A four-stage classification 
proposed by Krigel et al [57] was based entirely on tumour extent and was 
designed to include AIDS-associated KS as well as the "non-HIV epidemic" forms 
of the disease. A subsequent classification by Mitsuyasu, Groopman, and 
colleagues [58,59] designed specifically for AIDS-associated KS where patients are 
categorized according to extent of tumor and the presence or absence of systemic 
"8" symptoms and history of oral involvement (01). Chachoua et al [60]; later 
proposed a classification that included the presence or absence of "8" symptoms 
and oral involvement (01) and the CD4 count, but KS extent was not included as a 
staging variable. 
Currently, the most widely used staging system is that proposed in 1988 by the 
Oncology Committee of the AIDS Clinical Trials Group (ACTG) [61]. This system 
takes tumor distribution, CD4 count, HIV-associated symptoms, and opportunistic 
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complications into account, and separates patients into good-risk and poor-risk 
groups for each of these three variables (Table 4). Subjecting this classification to 
prospective validation revealed each of the three variables to be significantly 
associated with survival [62]. In multivariate analysis, only the CD4 count and 
tumour extent were significantly associated with survival, however subsequent 
analyses suggest that a lower CD4 count (i.e. 150 cellsjmm3) may be a better 
prognostic discriminate for survival than the originally proposed 200 cellsjmm3 
cut-off. This study was performed on patients treated prior to the introduction of 
effective ART, and its current relevance has not been tested. 
Confined to skin and/or 
lymph nodes and/or 
minimal oral disease* 
Tumour-associated 
oedema or ulceration 
Extensive oral KS 
Gastrointestinal KS 
KS in other non-nodal viscera 
mm3 CD4 cells < 1 
No history of OI or thrush History of OI and/or thrush 
No "B" symptoms # "B" symptoms present 
Performance status >/= 70 Performance status <70 
Table 5: ACTG Staging Classification for AIDS-Associated Kaposi's sarcoma 
* Minimal nodal disease is non-nodular KS confined to the palate. 
# "B" symptoms are unexplained fever, night sweats, > 10% involuntary weight loss, or diarrhoea persisting more than 
2 weeks. 
The above classification is applicable to: Classical Kaposi's sarcoma, Endemic Kaposi's sarcoma, Epidemic [AIDS-related] 
Kaposi's sarcoma With involvement of: cutaneous or muco-cutaneous structures, Lymph nodes or Viscera . 
The revised CD4 cutoff of 150 celis/ # L40 is lower than the original proposal of 200 celis/ #L. However, in the HAART era, 
CD4 count do not appear to correlate with prognosis 
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3.9 Diagnosis: 
The diagnosis of KS in an individual known to be HIV positive is usually straight 
forward. The characteristic appearance of the cutaneous lesions in the form of 
pigmented macules, plaques, papules, or nodules that range in colour from brown 
or brown-red to reddish purple are sufficient to establish the diagnosis. They can 
range in size from a few millimetres to large confluent areas many centimetres in 
diameter. Lesions can involve any area of the skin but are common on the soles of 
the feet and rarely affects the palms of the hands. 
Since the clinical appearance is so characteristic to the trained eye, biopsy can be 
reserved for those cases where there is clinical doubt. Biopsy confirmation 
establishes histological diagnosis. Suspected pulmonary lesions can be detected by 
bronchoscopy, but are generally not biopsied due to low yield and risk of 
haemorrhage. Chest x-rays and pulmonary gallium scans can also be used for 
evaluation. The concurrent presence of pulmonary infiltrates and nodular densities 
on chest x-ray, the lack of uptake of gallium in the pulmonary parenchyma and 
the presence of blood streaked sputum is virtually diagnostic for pulmonary KS 
when infectious causes have been ruled out. Kaposi Sarcoma involving the 
gastrointestinal tract is best diagnosed visually on endoscopy; biopsies are 
frequently negative because the lesions are sub-mucosal. 
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3.10 Treatment: 
The patient with AIDS-related malignancy presents two complex life-threatening 
diseases. Providing optimal treatment requires that the clinical team have a 
considerable understanding of HIV and the associated malignancy. 
Therapeutic approaches of HIV-KS must take into account that there is no curative 
therapy, that the natural course of the disease may be quite variable and that a 
large numbers of systemic approaches have immunosuppressive effects. Many 
factors must be evaluated in developing a treatment strategy; the type of KS, the 
extent and location of the tumour, the organs involved, the presence of tumour-
associated symptoms (e.g. pain, oedema, GI bleeding), symptoms of HIV 
infection, and the status of the patient's immune system. Kaposi Sarcoma may 
affect quality of life in a variety of ways; tumour-associated oedema may cause 
difficulty with ambulation; plaque-like or ulcerated cutaneous lesions may be 
painful, and bulky oral disease may interfere with speech or swallowing. In severe 
cases, bronchopulmonary involvement may lead to respiratory compromise, so the 
normal rules of palliative treatment should apply: in particular the concept that the 
treatment should not be worse than the disease itself. Variety of treatments have 
been used to treat HIV-KS and a range of responses been reported, however KS 
remains an incurable tumour. 
Management for HIV-KS includes systemic and local treatment modalities. 
Systemic treatment includes chemotherapy, immunotherapy and antiviral drugs. 
Local treatment include, conventional and megavoltage radiotherapy, cryotherapy, 
intralesional chemotherapy and topical retinoids. 
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Although several chemotherapy agents have proven effective in controlling KS, the 
responses are often of limited duration and don't clearly improve survival. Neither 
local nor systemic treatments for AIDS-KS have been shown to prolong survival. 
Treatment with effective a ntiretroviral therapy (ART) has led to a dramatic decline 
in KS incidence. ART reduces the risk of KS by 50%. Anti-neoplastic treatment, in 
combination with ART that suppresses HIV replication, may produce prolonged 
remission of KS [63, 64]. Palliation of symptoms and improvement of quality of life 
remain major goals of treatment. 
3.10.1 Antiretroviral therapy and Kaposi Sarcoma: 
The use of antiretroviral therapy started in the late 1980s; monotherapy with 
Zidovudine (azidothymidine, AZT) was shown to improve prognosis and clinical 
response in patients with HIV-related immunosuppression. This was attributed to 
improved immunity as reflected by reduced HIV viraemia and improved CD4 
lymphocyte count [63]. 
Despite improvement in response, improved immunity was transient due to the 
emergence of therapy resistant new HIV strains [66]. In mid 1990s protease 
inhibitors were introduced and licensed for use. 
Protease inhibitors act by blocking HIV replication for long periods of time. Clinical 
trials showed that the use of protease inhibitors combination was associated with 





Since the introduction of highly active antiretroviral therapy (HAART) in 1996 for 
HIV infection, the clinical outcomes for persons living with AIDS have improved 
significantly, and this includes those affected by neoplastic disease [68]. Highly 
active antiretroviral therapy has dramatically reduced the incidence of Kaposi's 
sarcoma, KS response rates have improved when HAART has been administrated 
with chemotherapy [69]. The clinical response was attributed to improvements in 
immunity reflected by an increase in CD4 cell counts [70]. 
3.10.2 Systemic therapy: 
3.10.2.1 Chemotherapy: 
Several cytotoxic chemotherapeutic agents were used and found to produce 
profound response with acceptable degree of side effects [71]. Chemotherapy can 
be used as a single agent or in combinations. 
Agents such as vinca alkaloids (vincristine, vinblastine), bleomycin, doxorubicine, 
etoposide and topoisomerase inhibitors are active against HIV-KS. Chemotherapy 
is generally indicated in progressive, extensive cutaneous disease where rapid 
response is desired or in systemic visceral involvement. Several studies showed 
that the combined chemotherapy is highly effective in producing good clinical 
response and palliation of symptoms i.e. decreased oedema, decreased pain as 
well as improving systemic symptoms. The most frequently used combination 
chemotherapy regimens are doxorucin, vincrstine and bleomycin (ABV) and 
Bleomycin with vincristine (BV). 
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The doses of the commonly used chemotherapy agents are relatively high, 
doxorubicin 40 mg/m2 every 4 weeks or 20 mg/m2 every 2 weeks, vincristine 2 
mg/m2, Bleomycin 10 I.U /m2. Cycles are repeated every 4 weeks. The ABV 
regimen was regarded as the standard of care for HIV-KS in the U.S. In South 
Africa, in the public sector and in most resource poor countries ABV has remained 
as an active, relatively tolerable and cost-effective regimen. However the 
treatment with conventional chemotherapy agents has been frequently limited 
with toxic effects and with the immunosuppressed status of HIV patients and their 
opportunistic infections, this led to the development of new chemotherapy 
approaches, the liposomal anthracyclines and paclitaxol [72]. 
Liposomal anthracyclines: 
A liposomal formulation of the chemotherapeutic agents is a new approach to a 
variety of malignant diseases. Liposomes are lipid and lipoprotein vesicles that 
encapsulate the active chemotherapy agent increasing their potential for targeting 
the tumour and thus reducing the toxic effects to normal tissues. The new 
formulation of anthracyclines results in longer plasma half life with smaller volume 
of distribution than the non-encapsulated form and higher drug concentration in 
KS tissue [73, 74]. Early clinical trials showed that Liposomal anthracyclines as a 
single agent chemotherapy has a clinical response equal or even better than ABV 
with less toxic effects [75]. 
Liposomal anthracyclines (Liposomal doxorubicin and daunorubicin) are currently 





This chemotherapeutic agent has been developed and approved as second line 
therapy of AIDS-KS. Paclitaxol has shown substantial response rates and 
significant single agent activity both in patients with refractory tumours as well as 
in patients where paclitaxol used as first line treatment. Doses used are in the 
range of 100-135 mg/m2 every 3 weeks. 
Investigational and experimental treatments of KS: 
Several investigational drugs for the treatment of Kaposi's sarcoma are under 
evaluation, these include antiangiogenesis compounds, cytokine inhibitors; signal 
transduction inhibitors, thalidomide and anti-HHV8 agents. 
Anti-angiogenesis Compounds: 
These investigational drugs act by inhibiting new blood vessel formation. Kaposi 
Sarcoma is highly vascular tumour with abundant amounts of VEGF. Inhibitors of 
VEGF are currently under evaluation and their use is restricted to clinical trials 
[77]. 
Cytokine Inhibitors: 
Cytokines playa role in the pathogenesis of Kaposi Sarcoma; cytokines stimulate 
the growth and proliferation of KS cells. Targeted cytokine therapy is being 
evaluated; these include immunomodulation of some of the known cytokines such 
as IL-6, Bfgf, IL-6 monoclonal antibody. IL-4, downregulates IL-6 production and 
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retinoid compounds such as tretinoin. Interferon a is used as a modulator of bFGF 
which reduces the production of bFGF and induces apoptosis [78]. 
3.10.2.2 Anti HHV8: 
Inhibition of HHV-8 can be suitable for both prevention and treatment of AIDS-KS. 
It has been shown that HHV-8 is sensitive to some antiviral drugs that prevent the 
replication of HHV-8. Sensitivity of HHV-8 to antiviral antibiotics ranges from high 
to cidofovir, moderate to ganciclovir and foscarnet and weak to acyclovir [79; 80]. 
3.10.2.3 Immunotherapy: 
Interferon a has been in use as an active agent for localized skin KS lesions for 
more than two decades. Interferon has immunomodulation, antiviral and 
antiangiogenesis effects [81, 82]. A dose of 1-10million units/day is used; the 
dose is usually lowered when it is used with antiviral drugs to 1-5 million 




3.10.3 Local therapy: 
3.10.3.1. Topical retinoids 
Introduction 
As mentioned earlier Retinoid compounds act as immunompdulators of IL-6 which 
is involved in the pathogenesis of AIDS-KS. Retinoids induce a range of biological 
effects that include: cell growth inhibition, induction of normal cellular 
differentiation and initiation of apoptosis [84]. These effects are mediated through 
the binding of retinoid compound (Cis and Trans compounds) to intracellular 
retinoic acid receptors Le., RAR-o, RAR-~, RAR-y and retinoic acid X receptors 
RXR-o, RXR-~, RXR-y [85]. 
The anti-proliferative and anti-tumour effects of retinoid compounds in vitro justify 
the rationale for their use in clinical trials [86, 87]. 9-cis-retinoic acid (alitretinoin 
[Panretin]) gel has received FDA approval for clinical use for treatment of localized 
cutaneous KS lesions. 
3.10.3.2 Radiation therapy 
Kaposi sarcoma is highly radiosensitive tumour; radiotherapy is considered the 
mainstay for palliative treatment of localized disease with extremely high rates of 
local control. Radiotherapy improves local symptoms of pain, oedema and 
bleeding. Excellent palliation of symptoms can be obtained with low energy 
electron therapy (6 Mev); doses of 800 cGy in single fraction, 2000-3000 cGy in 10 
fractions can be use depending on site of lesions. Most superficial cutaneous 
lesions are treated with a large single fraction dose of 800 cGy. Lesions in other 
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areas like genital organs, hands and conjunctiva are treated with higher 
fractionated doses. 
Since HAART was introduced for treatment of HIV, the natural history of HIV has 
changed significantly; this resulted in less practice of palliative radiotherapy and 
changes the trend and intention to more radical approaches. 
3.10.3.3 Intralesional chemotherapy 
Intralesional injection of vinblastine showed relatively high response but for short 
duration [88, 89, 90]. 
3.10.3.4 Cryotherapy 
Liquid nitrogen was used primarily by dermatologists for palliative treatment of 
lesions of hands, face and neck with partial to complete response; cryotherapy 
can cause permanent hypopigmentation [91]. 
3.10.3.5 Surgical excision 
Although local surgical exciSion has been tried in certain sites such as oral cavity, 
shaft of the penis and eyelid leSions, however it doesn't seem to be reasonable as 
KS is a systemic disease. 
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4. HIV and Kaposi sarcoma in South Africa: 
South Africa faces a major health problem with HIV infection and its associated 
opportunistic infections and malignant diseases. South Africa has one of the 
highest and fast growing HIV epidemics in the world. It's estimated that there are 
approximately 5 million or 1 in 10 South Africans are now HIV positive, this 
accounts of about 20% of adults aged 15-49 year [92]. Examinations of women of 
childbearing age at antenatal clinics reveal a non-uniform geographical distribution 
throughout the country. The highest prevalence is in the province of Kwazulu 
Natal (35-40%); the lowest is in the Western Cape (7-8%); with intermediate 






Figure 3: prevalence of HIV in South Africa 
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The impact on child health and infant mortality is also high, it's estimated that 
between 61,000- 89,000 newly infected children born annually to HIV-infected 
mothers; this contributes to higher childhood mortality rate. 
HIV-related deaths account for about 40% of all deaths since HIV was recognized 
as an epidemic according to the medical research council (MRC) of South Africa, 




average of 53 years [92, 93]. Kaposi Sarcoma in South Africa was recognized as 
an endemic even before HIV, although the incidence of KS has risen up as the HIV 
epidemic grows [94]. Data from the cancer registry of South Africa showed that 
KS incidence was doubled and increased by seven folds in men and women 
respectively for the period 1992-1996 [95]. HHV8 is considered the major cause of 
HIV-KS. The prevalence of HHV8 is high in populations at high risk of KS i.e. HIV 
infected homosexual men and African population where KS has been endemiC for 
long [96, 97, 98]. 
A recent study of African patients from Johannesburg and Soweto showed that 
HHV8 infection was strongly associated with KS [99]. Risk of KS was increased 
with increase antibody titer of HHV8, however for a given titer of HHV8 the risk 
was greater in HIV seropositive than seronegative subjects. It would seem that 
high HHV8 antibody titer reflects a high HHV8 viral load though only little data 
support this at the present time [99]. 
In three studies, it has been shown that seroprevalence of HHV8 in South Africa 
tend to increase with age and decrease with level of education. In the 
Johannesburg and Soweto study of black African patients the seroprevalence of 
HHV8 was slightly more than 30% compared with 20% of black blood donors and 
5% in white blood donors. There was no sex variation [99, 100, 101]. The mode 
of transmission is still to be clarified, in South Africa there is weak evidence of 
sexual transmission as the prevalence of HHV8 is similar in individuals with or 




5. Evaluation of outcome: 
Despite all the advances in treatment, HIV-KS remains a major cause of morbidity 
and mortality in HIV infected individuals. Evaluation of outcome is measured in 
terms of clinical response and survival; however outcome is so far, determined by 
the degree and severity of immunosuppression (CD4 count) which seems to be 
inadequate for such assessment and needs to be reviewed with the new policy. 
The average annual mortality rate of HIV-KS is approximately 40% and the 
median survival is 18 months from the time of diagnosis, taking into consideration 
that therapeutic interventions have far been suboptimal [102]. 
Unfortunately only little attention has been paid to the evaluation of outcome of 
HIV-KS and to the fact that the impact of the problem on survival is poor and the 
response is short-lived with the best palliative measures available. 
In the year 2001, an audit of the patients with HIV-KS was done in the Oncology 
department at King Edward VIII hospital in Durban, South Africa. A total of 80 
patients were evaluated for outcome, 42 males and 38 females. All patients had 
extensive mucocutaneous KS necessitating systemic therapy. Due to resource 
constraints; only 10/80 (12.5%) received chemotherapy according to oncology 
guidelines at that time. Of the remainder, 10/80 (12.5%) received no therapy at 
all and the majority, 60/80 (75%) patients were given palliative radiotherapy in a 
single dose to the area of greatest tumor burden. Only little symptomatic relief 
was obtained with the treatment approach mentioned. 
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As the treatment is considered suboptimal, we in Kwazulu-Natal have tried to 
establish a new strategy of definitive treatment with an appropriate, safe and 
effective therapeutic regimen. In view of this complexity and further more with the 
limited resources, providing treatment for all patients might not be an easy task. 
Hence the rationale for this study is to evaluate and identify several variables in a 
small cohort of patients over 6 months and to see if these variables can be 
predictive of response and survival. This is particularly relevant in South Africa, 
with the already high seroprevalence rates of HIV and HHV8, so that therapy and 
resources can be more appropriately directed. In the long term, these parameters 
may dictate a policy on selection criteria for therapy of patients with HIV-KS. 
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Chapter 2 
2.1 AIM 
The aim of the study is to identify which pre-treatment parameters were associated 
with therapeutic response in a group of patients with AIDS-associated Kaposi 
Sarcoma treated with HAART and chemotherapy and which of these parameters can 
be of prognostic value. 
2.2 OBJECTIVES 
1. To document clinical, haematological, immunological and biochemical 
parameters in all patients of HIV-KS at baseline and month 6 to be 
treated with chemotherapy. 
2. To document outcome with respect to response to therapy and survival in all 
patients with HIV-KS who received standard chemotherapy and HAART at 6 
months. 
3. To evaluate which of these parameters is of prognostic value. 
4. To assess the predictive value of change of certain parameters i.e. CD4, VL 




Patients and Methods 
2.3 HYPOTHESIS 
Patients with AIDS-associated Kaposi sarcoma who present with low Haemoglobin 
and S.albumin and low counts of CD4, WBCs, Lymphocytes, neutrophils have poor 
prognosis and poor response to treatment. 
2.4 METHODS 
This is an analysis of data from a prospective randomized controlled open-labelled 
phase III trial of patients with HIV-associated Kaposi sarcoma comparing HAART 
alone with the combination of HAART and chemotherapy. The study was approved by 
the research ethics committee and the postgraduate education committee of the 
University of KwaZulu-Natal. The study was performed at King Edward VIII hospital 
(KEH VIII) and Inkosi Albert Luthuli Central hospital (IALCH), two of major tertiary 
health care referral hospitals of the province of KwaZulu-Natal which has the highest 
prevalence of HIV infection throughout South Africa. Patients recruited for the study 
are seen at the Dermatology and Oncology clinics at KEH VIII and IALCH. 
All patients referred to the study site are informed about the study; only those who 
gave informed consent were enrolled. In addition, consent was taken for 
photography in each patient. Patients were counselled about HIV test and have their 
lesions biopsied. Serological evidence of HIV and histologically confirmed Kaposi 
Sarcoma were required. Patients are staged into good risk and poor risk according to 
the AIDS clinical trial group (ACTG) criteria, which are based on extent of tumour (T), 
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the status of immune system (1) as measured by the count of CD4 cells and the 
extent of systemic illness (5), refer to chapter one for more details about ACTG 
staging system of AIDS-KS. Data from records of 25 patients who form part of this 
prospective trial were collected at base line (time at presentation) and again at 6 
months with exception of demographic data that were taken only at presentation. 
Data collected included: 
• Epidemiological data: Age, Gender, Occupation, Ethnic group, Marital 
status, Level of education. 
• Clinical data: Stage of disease according to ACTG. 
• Haematological data: Haemoglobin, WBCs, Platelets, Lymphocytes, 
Neutrophils, Monocytes, Eosinophils and Basophils. 
• Immunological data: CD4 count 
• Biochemical data: Liver function tests, Kidney function. 
• Viral data: plasma HIV serology and plasma HIV viral load 





Patients and Methods 
Treatment consists of: 
HAART: one tablet daily of Triomune: 
• Stavudine 40 mg BD for patients > 60 kg 
30 mg BD for patients < 60 kg 
• Lamivudine 150 mg BD for patients >50kg 
2 mg/ kg for patients < 50 kg 
• Nevirapine 200 mg BD 
(200 mg daily for first 2 weeks) 
Chemotherapy: administered at 3 weekly intervals and consists of: 
• Doxorubicin 20 mg / m2 intravenously 
• Bleomycin 10 U / m2 intramuscularly 
• Vincrstine 1.4 mg / m2 intravenously, maximum dose 2mg 
Chemotherapy will continue for 2 cycles after maximum response unless toxicity 
developed. Maximum cumulative doses are 400 mg/ m2 for Doxorubicin and 200 
U/m2 for Bleomycin. 
At the initial visit 2.5 mls of venous blood were taken to confirm the HIV status of the 
patient. On the second visit 30 mls of venous blood were taken for haematological, 
chemical, immunological and virological studies, these included: FBC, LFT, U/E, CD4, 
HIV RNA Viral load. FBC and blood chemistries were repeated at 2 weekly intervals 
where 5 mls of blood were taken. At week 24, 30 mls of blood were taken for 
immunologic and virologic studies. 
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Tissue sample were taken at the initial visit for diagnostic purposes which was used 
for HIV-l loads. 
2 4 6 12 24 48 
x x x x 
x x x x 
x x x x 
Table 6: parameters and timing for patient assessment 
2.5 Definition of response 
Response to treatment was assessed by measurement of the above mentioned 
parameters at month 6 as per ACTG criteria, i.e. complete response, partial response, 
minimal response (stable disease) or disease progression. 
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Complete response (CR): absence of all evidence of disease and no appearance of 
new disease at least for 4 weeks. 
Partial response (PR): reduction by at least 50% in the number of all previously 
existing lesions maintained for at least 4 weeks, with no new skin or oral or new 
visceral lesions. 
Minimal response (stable disease): any response less than partial response or where 
neither PR nor PD criteria met. 
Progressive disease (PD): more than 25% increase in one or more lesions or 
appearance of new lesions. 
Statistical analysis: 
Data were analyzed in SPSS version 11.5 (SPSS Inc, Chicago, III, USA). Non-
parametric statistics were used because of the small sample size and the skewness of 
the data. Variables were described using medians and ranges, and compared 
between two independent groups using Mann-Whitney tests. Baseline and 6 month 
comparisons were done using Wilcoxon signed ranks tests. ROC curves were used to 








A total of twenty-five consecutive patients were evaluated over a period of 6 months 
at the dermatology clinic, King Edward VIII hospital as participants of a prospective 
randomized controlled open-labelled phase III trial of patients with HIV-associated 
Kaposi sarcoma comparing HAART alone with the combination of HAART and 
chemotherapy. 
Of the twenty five patients 16(64%) were males and 9(36%) were females with a 
male to female ratio of 2.7:1. Ages ranged between 24 to 47 years with a median 
age of 34 years. All patients were of African ethnicity and Isizulu speaking. 
With regard of education 4(16%) had primary school education, 17(68%) had 
secondary school education, 3(12%) had tertiary level education while 1(4%) was 
uneducated. 
Nineteen (76%) were single, 3(12%) were married, 3(12%) were living together. 
With respect of occupation, 1(4%) was a housewife, H( 44%) were labourers, 2(8%) 
were office workers, 1(4%) was a professional employee, 9(36%) were unemployed 




Gender No % 
19 64 Male 
36 6 Female 
25 100 Total 
Age 
Median 34 
Range 25 - 47 
Ethnic origin 
African 25 100 
Occupation 
House wife 1 4 
Labourer 11 44 
Office worker 2 8 
Professional 1 4 
Unemployed 9 36 
Other 1 4 
Total 25 100 
Marital status 
Single 19 76 
Married 3 12 
Living together 3 12 
Total 25 100 
Home Language 
Isizulu 25 100 
Level of education 
Primary 4 16 
Secondary 17 68 
Tertiary 3 12 
None 1 4 
Total 25 100 
Urban or Rural 
Urban 14 56 
Rural 11 44 
Total 25 100 




All patients were from the HAART and chemotherapy arm i.e. all were treated with 
the combination of HAART and chemotherapy. 
All of the twenty-five (100%) patients had their haematological, biochemical, 
Virological and clinical parameters measured at base line. At month 6 only 22(88%) 
patients were alive, 3 (12%) patients died before 6 months, re-measurements of the 
same parameters was possible only for the 22 patients who remained alive. 
3.2 Blood parameters 
Blood parameters were measured at baseline and month 6, the median values at 
base line were as follows: Hb 10.9 g/dl, WBCs 5.95x109/L, lymphocytes 1.7 x109/L, 
neutrophils 3 x109/L, platelets 272 x109/L, S.albumin 30 gil, total protein 88 gil, ALP 
64 U/L, and GTI 21 U/L. At month 6 the median values of the same parameters 
were, Hb 12.2 g/dl, WBCs 4.65 x10*9jL, lymphocytes 1.5 x109/L, neutrophils 3 
x109/L, platelets 301 x109/L, S.albumin 36.5 gil, total protein 84.5 gil, ALP 78.5 U/L, 
GTI 44.5 U/L. Summary of all the values at baseline and month 6 is given table 8 
below 
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Median values of selected 
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Figure 4: Baseline and month 6 blood parameters of patients on combination therapy 
Normal values Base line Month 6 
Hb 11.5- 15.5 g/dl 10.9 12.2 
WBe 4-11xl0
9/L 5.95 4.65 
Lymphocytes 20-450/0 x 109/L 1.7 1.5 
Neutrophils 40-75% x 10
9/L 3 3 
Platelets 150-400 x 10
9/L 272 301 
S.albumin 35-50gm/L 30 36.5 
Protein 60-80gm/L 88 84.5 
ALP 30-300iu/L 64 78.5 
GGT 8-60 U/L 21 44.5 





The median CD4 count was 255 cells/mm 3 (range 1-618) at baseline for the entire 
group of patients, at month 6 only 22 patients remained alive; their median CD4 
count was 383.5 cells/mm 3 (range 84-1028), the median CD4 count for the 3 
patients who died before month 6 was 47 cells/mm3 (range1 - 175). A change of CD4 
count from baseline to month 6 was observed, median CD4 count was increased by 
122.5 cells/mm 3 (p=<O.OOl), 
3.4 Virology 
The median HIV-RNA viral load was 42000 (4.6910glO) (range 4700 to 720000) for 
the total number of patients at base line. For those who remained alive at month 6 
the median viral load was 50500(4.69 10glO) (range 4700 to 720000). 3 patients died 
before month 6 for whom the median viral load was 31000(4.5 10glO) at baseline. VL 
decreased by a median of 2.88 logs from baseline to 6 months. At month 6 the 
median log viral load was 1.70, 90.9% of patients reached very low detectable or 
even undetectable levels of VLs (P= <0.001). 
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Figure 5: Figure demonstrating median CD4 recovery and viral load decline over a six 
month period (error bars show inter-quartile ranges) 
3.5 Therapeutic response 
21 (84%) patients were assessed for response as 4 (16%) patients did not reach 
month 6. Of the 21 patients 14 (66.6%) were males and 7 (33.3%) were females; 3 
(14.3%) had complete response and 18(85.7%) had partial response. With respect to 
sex 2(14.3%) males had complete response and 12(85.7%) has partial response, 





Figure 6a and 6b patient on combination chemotherapy and HAART before therapy 
Figure 6a Figure 6b 
Figure 7a Figure 7b 
Figure 7a and 7b patient on combination chemotherapy and HAART after 6 months of therapy, 
demonstrating a partial response 
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3.6 Survival 
3 patients died before month 6, their baseline haematological and immunological 
parameters are shown in the table below: 
Baseline Baseline Baseline Baseline Baseline Baseline Baseline CD4B logVL 
haem platelets WBC neutrophils lymphocytes monocytes eosin baseline 
1 12.3 324 3.8 - - - - 47 4.00 
2 9.8 284 7.7 5.9 1.0 .7 .10 175 4.78 
3 9.2 113 6.8 2.6 2.7 1.3 .20 1 4.49 
Total 3 3 3 2 2 2 2 3 3 
N 
Table 9: Baseline values for selected parameters for patients who demise before 
month 6 
One patient was randomized to chemotherapy had low CD4 count and demised even 
before he received chemotherapy. Viral loads on HAART declined but CD4 did not 
recover. 
Another patient received chemotherapy and HAART and developed liver impairment, 
after 2 months of therapy, most likely due to chemotherapy or Nevirapine. 
The other patient was randomized to chemotherapy but due to very low CD4 count, 
did not receive it and demised due to severe immunosuppression and developed 
AIDS dementia terminally (Viral loads on HAART declined but CD4 did not recover). 
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3.7 Correlation with demographic factors 
3.7.1 Age: 
There was no significant difference in mean age between those who had a complete 
response (mean = 33.67 years) and those who had a partial response (mean = 
34.72) (p = 0.758). 
Overall response Std. Error 
attained since N Mean Std. Deviation Mean 
P value 
entry /baseli ne 
Age Complete 3 33.67 8.505 4.910 0.758 
Partial response 18 34.72 4.933 1.163 
Table 10: Age - Response correlation in 21 patients 
3.7.2 Gender: 
Of the 21 patients who could be assessed for response, 2(14.3%) males had 
complete response and 12(85.7%) has partial response, 1(14.3%) female had 
complete response and 6 (85.7%) had partial response, i.e. males and females have 
exactly the same response rate with regard to complete and partial response. There 




Overall response attained since 
entry/baseline 
Complete Partial response Total 
Sex Male Count 2 12 14 
% within Sex 
14.3% 85.7% 100.0% 
Female Count 1 6 7 
% within Sex 
14.3% 85.7% 100.0% 
Total Count 3 18 21 
% within Sex 
14.3% 85.7% 100.0% 
Table 11: Sex * Overall response attained since entry/baseline Cross tabulation 
Chi-Square Tests 
Asymp. Sig. (2- Exact Sig. (2- Exact Sig. (1-
Value df sided) sided) sided) 
Pearson Chi-Square .000(b) 1 1.000 
Continuity Correction (a) .000 1 1.000 
Likelihood Ratio .000 1 1.000 
Fisher's Exact Test 1.000 .726 
Linear-by-Linear 
.000 1 1.000 Association 
N of Valid cases 21 
a Computed only for a 2x2 table 
b 2 cells (50.0%) have expected count less than 5. The minimum expected count is 1.00. 
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3.7.3 ACTG staging 
Of the 21 patients, 15 (71.4%) were of good prognosis and 6(28.6%) were of poor 
prognosis, 3(14.3%) had complete response and 18(85.7%) had partial response. 
The complete response in the good prognosis group was 20 % higher than the poor 
prognosis group, however wasn't statistically significant (p=0.526). The poor 
prognosis group was significantly associated with deaths by 33.3 % higher than the 
good prognosis group (p =0.037). Odds ratio could not be calculated because there 
were no participants in the good prognosis group who died; hence the reporting in 
percentage rather than odds ratio. 
Overall response attained since 
entry/baseline 
Partial 
Complete reSDonse Total Prognosis poor Count 0 6 6 
% within 
Prognosis .0% 100.0% 100.0% 
good Count 3 12 15 
% within 
20.0% Prognosis 80.0% 100.0% 
Total Count 3 18 21 
% within 
PrOQnosis 14.3% 85.7% 100.0% 




Chapter 3 Results 
Died before 6 month visit Total 
no yes 
Prognosis poor Count 6 3 9 
% within 
66.7% 33.3% 100.0% Prognosis 
good Count 16 0 16 
% within 
100.0% .0% 100.0% Prognosis 
Total Count 22 3 25 
% within 
88.0% 12.0% 100.0% Proanosis 
Fisher's exact p value = 0.037 
Table 13: Prognosis * Died before 6 month visit Cross tabulation 
Chi-Square Tests 
Exact Sig. (2- Exact Sig. (1-
Value df Asymp. Sig. (2-sided) sided) sided) 
Pearson Chi-Square 6.061(b) 1 .014 
Continuity Correction (a) 3.315 1 .069 
likelihood Ratio 
6.889 1 .009 
Fisher's Exact Test 
.037 .037 
Linear-by-Linear Association 
5.818 1 .016 
N of Valid Cases 
25 
a Computed only for a 2x2 table 





3.8 Correlation with blood parameters 
3.8.1 Haemoglobin 
Comparison of baseline Hb between complete and partial response groups did not 
show any significance (p=0.580) according to the· statistical test applied (Mann-
Whitney test). 
3.8.2 Total WCC and lymphocyte count 
Baseline WBCs and lymphocytes were significantly different for those who had 
complete response and those who had partial response with p values of 0.009 and 
0.035 respectively. 
WBCs showed 100% sensitivity and 93.3% specificity at a cut-off value of 9.7 while 
lymphocytes showed similar sensitivity and specificity at a cut-off value of 2.25. 
ROC Curves (Receiver Operating Characteristic curves): 
It is a graphical representation of the trade off between the false negative and false 
posi,tive rates for different possible cut points of a diagnostic test, equivalently, the 
ROC curve is the representation of the tradeoffs between sensitivity (Sn) and 
specificity (Sp). 
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1. It shows the tradeoff between sensitivity and specificity (any increase in sensitivity 
will be accompanied by a decrease in specificity). 
2. The closer the curve follows the left-hand border and then the top border of the 
ROC space, the more accurate the test. 
3. The closer the curve comes to the 4S-degree diagonal of the ROC space, the less 
accurate the test. 
4. In this study, ROC curves were used to predict death and response using 
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Figure 9: Baseline lymphocytes ROC curve 
3.8.3 Liver enzymes 
All blood parameters measured at base line were comparable for those who survived 
and who have died before month 6 with exception of ALP (P=O. 006) and Gamma GT 
(P=O. 001) which were much higher for those who died. GGT and ALP showed 100% 
sensitivity values of 70 and 84.5 respectively. 
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N53ALKAL.1: 5.3 
Died before 6 month Alkaline N53GAMMA.1: 5.3 
visit phosphatase GGT 
No 21 Median 59.50 20.00 
Minimum 5 5 
Maximum 115 69 
Yes 3 Median 137.00 110.00 
Minimum 90 71 
Maximum 161 145 
P value 0.006 0.001 
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Figure 11: Baseline GTI ROC curve 
3.9 Correlation with CD4 
There was slight negative correlation between CD4 and log VL at baseline but it 
wasn't statistically significant (Spearman's rho=-0.115, p = 0.585). 
Baseline CD4 count was higher in patients who remain alive than those who died at 
month 6, 288 cellsjmm 3 and 47 cellsjmm 3 for both groups respectively. (P=0.058) 
which considered as borderline significant. Baseline VL was higher in those who 
remained alive compared to those who died, although VL wasn't statistically 
significant to predict death (p = 0.446). This may be difficult to interpret but since 







South Africa is one of the highest HIV-epidemic regions worldwide, it has the highest 
number of people living with HIV, the seroprevalence rate is approximately 20% of 
the total population. In Kwazulu-Natal where this study was conducted the 
prevalence of HIV is highest in the country and has been documented according to 
surveys in antenatal clinics to be 35-40%. 
Kaposi Sarcoma is the commonest AIDS-associated cancer. People infected with HIV 
are 100 to 300 times more likely to have KS, consequently the HIV-related deaths 
were greatly increased and life expectancy markedly shortened. In South Africa HIV-
related deaths account for approximately 40% of all deaths according to the Medical 
Research Council of South Africa [102]. 
In HIV patients, HIV-cancers present a complicated matter where general rules of 
cancer treatment don't apply. There are no well-defined rules or guidelines that 
standardize the treatment of HIV-related cancers in South Africa and in most 
provinces it is a departmental-driven protocol. These guidelines may be inappropriate 
and inadequate to provide control of the malignant disease. The treatment offered is 
usually the Simplest, most cost-effective, palliative treatment available. WhereHIV 




cytotoxic chemotherapy and radiotherapy will add to the already existing 
immunosuppressive status due to HIV, so control of HIV is an essential element to 
control cancer. 
In our oncology department, the number of HIV-KS patients seen is quite large and 
they are almost always offered palliative radiotherapy, this is due to multiple factors: 
absence of specific guidelines, large number of patients, low CD4 count at 
presentation, high incidence of opportunistic infections and deaths and no 
antiretrovirals available in the past. 
With the introduction of ARV therapy, all HIV patients will qualify and be eligible for 
ARVs; does this change the situation in South Africa? 
This led to the question of whether or not we can establish a new policy or strategy 
of selection of those to be treated for HIV-KS. Hence the purpose of this study is to 
identify various hematological, biochemical, immunological, virological and clinical 
variables that can be of potential value as predictors of response and prgnosis in HIV-
KS. This is the first study of its kind on Black African patients with HIV-KS. 
Unfortunately very few articles and little literature address the importance of these 
variables, however several retrospective studies evaluated some of these variables 
including age, gender, ethnic origin, CD4, CD8, plasma HIV load, p24 antigenaemia, 




nonetheless CD4 count and HIV viral load were most extensively studied. Evaluation 
of more variables is evolving. 
In our study we directed our evaluation towards some basic routinely used blood 
parameters. 
Our data analysis showed that age (mean= 34.52 years) and gender don't predict 
response; this is in contrast with Nasti et al [103], results which showed that KS at 
younger age was associated with more aggressive presentation, more severe 
immunodeficiency and more severe course in women, with shorter survival was seen 
more in women. In another study by the same author, survival wasn't influenced by 
age and sex. Most of other studies didn't show any association between age, and 
gender with response and prognosis. The association between ethnicity and response 
or prgnosis couldn't be assessed as all patients were of a similar ethnic origin. 
All hematological and biochemical blood parameters including Hb, WBCs, 
lymphocytes, neutrophis, Monocytes, basophile, S.albumin, total protein, liver 
enzymes, bilirubin and renal functions were measured at baseline and month 6. 
There is a dearth of such information in the literature, with an exception of one study 
by Spano JP et al [104], who retrospectively studied 78 HIV-infected patients; 
diagnosed as having KS between 1989 and 1995 with a median follow up of 22 




immunoglobulin A and G levels are independent predictors of prognosis. We found, in 
our 25 patients that the total neutrophil count was not predictive of response. 
The rest of blood parameters such as Hb, platelets and S.albumin were not 
statistically significant to predict response. 
In this study most of blood variables measured where comparable for those who 
survived and those who died before 6 months with exception of ALP (P=0.006) and 
Gamma GT (P=O.OOl) which were higher in those who died. The rest of liver 
parameters i.e. total protein, bilirubin, S.albumin and AL T were within normal limits 
for both those who died and who survived. This points toward the significance of 
Gamma GT and ALP as independent factors of survival. This is the first study to 
document the significance of liver enzymes as predictors of survival. Hence this has 
implications. Those with high GGT and ALP should be fully investigated before 
starting chemotherapy. These abnormalities may be due to a multitude of factors: 
Viral Hepatitis, TB, herbal use, alcohol or if it is not there at baseline and 
subsequently develops may be due to ARVs or due to the CXT itself, however hepatic 
infiltration by KS appear to be most likely cause, further imaging and biopsy would 
have elicited the most likely cause. 
Baseline WBCs (p=0.004) and lymphocytes (p=0.026) were significantly higher in 
those with complete response, WBCs showed 100% sensitivity and 93.3% specificity 
at a cutoff value of 9.7 while lymphocytes showed similar sensitivity and specificity at 
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a cutoff value of 2.25, Gamma GT and ALP showed 100% sensitivity values of 70 and 
84.5 respectively but with low specificity. This suggests that higher values of Gamma 
GT and ALP are associated with poor response and more deaths while WBCs and 
lymphocytes are highly sensitive measures and cutoff values can be used to predict 
response. 
With respect to immunological and virological variables CD4 and HIV viral load were 
used to assess response, baseline CD4 was higher in those who has survived to 
month 6 with borderline significance value (p=0.058). HIV viral load was higher in 
those who survived compared to those who died but wasn't statistically significant to 
predict survival. This is surprising and cannot be explained. There was slight negative 
correlation between CD4 count and log VL. At month 6 almost all patients showed 
very low or even undetectable levels of HIV VL, this is probably explained as a direct 
response to chemotherapy and HAART. Several studies showed diverse results with 
regard to CD4 count and VL, at the time Quinlivan et al [105], concluded that neither 
CD4 count nor HIV viral load predicted KS progression or KS clinical stage, Nasti et al 
[106] also concluded that CD4 count doesn't provide prognostic information. In 
contrast Hogg RS et al [107] demonstrated that low CD4 count « 200 cellsj mm3) 
was associated with KS progression and mortality, he concluded that there was low 
rates of disease progression and low mortality with CD4 counts of 200 cellsjmicroL or 





count was independently associated with shorter survival and best predicts over all 
survival. 
Correlation of prognosis with CD4 changes over time doesn't show to be significant, 
as for both the good and poor prgnosis groups the change in CD4 count was at a 
similar rate at baseline and at month 6; in other words categorizing patients as good 
and poor prognosis groups can't predict the rate of CD4 count increase. 
Similarly correlation of HIV viral load with prognosis doesn't provide significant 
information i.e. there was no difference for good and poor prgnosis in terms of VL 
changes over time, so again prognosis doesn't affect the rate of VL change. Although 
the change of CD4 (p= 0.002) and VL (p=O.OOO) was significant over time which 
most likely is attributed to response to treatment, such change doesn't predict which 
patients will have either complete or partial response as there was no significant 
difference in CD4 and VL change between those who had complete or partial 
response. 
There was a trend towards good prgnosis associated with complete response; 
complete response was 20% higher in the good prgnosis than the poor prgnosis 
group, however the difference wasn't statistically significant (p=0.S26) probably due 
to the small sample size. Poor prognosis was associated with 33.3% (p=0.037) more 
deaths than the good prgnosis. 
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Study limitations: 
1. Sample size is small but it's equally true that some of the variables may have 
reached statistical significance with a larger sample size. 
2. Short follow up time of 6 months. Here again, we may have seen some 
variables unfold with respect to prognosis if the period of follow up had been 
longer. 
3. Poor or uneven distribution of CR vs PRo Because there are so few with CR 
and most have PR, it is difficult to compare the groups. 
4. This study was basically a prospective one, collected from data of a 
therapeutic trial. The initial study design and number of participants calculated 
was not powered or specific for a study addressing the prognostic indicators. 







Epidemic AIDS-KS is the most common AIDS-associated malignancy. HIV patients 
who develop Kaposi Sarcoma present a complex situation. Palliative radiotherapy has 
been the corner stone for cutaneous and muco-cutaneous KS lesions, since 
chemotherapy in patients with AIDS, in the absence of antiretroviral therapy is riddled 
with problems. In the light of the national ARV rollout, there is a need to re-establish 
selection guidelines for therapy of HIV-KS. 
Although our cohort is small, it questions the reliability of a variety of parameters as 
potential predictors of outcome and response in HIV-KS. Although it's difficult to 
predict from the initial presentation which patients are most likely to have a good 
response or a rapidly progressive tumors, our finding concluded that the use of 
simple, cheap, routinely used parameters such as WBCs (P=O.004), lymphocytes 
(P=O.026), ALP (P=O.06), GGT (P=O.OOl) appear to be of value to predict 
therapeutic response and survival where resources are limited. Whereas WBCs and 
lymphocytes were good predictors of response, ALP and GGT were associated with 
poor response. 
Although CD4 and VL have been evaluated in many studies and results were diverse 
with respect of response and prognosis prediction, our findings showed that CD4 and 
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VL are poor predictors of prognosis and therapeutic response. These results can be 
used to define a new policy on selection criteria for therapy of patients with HIV-KS 
taking into account that access to this kind of therapy adds an extra burden on health 
care services. 
Further studies with a larger sample size and longer period of evaluation are 
recommended to evaluate these parameters in order to establish clearer guidelines 
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